TESSA THERAPEUTICS
Tessa Therapeutics is a provider of therapy designed to focus on T cell therapy for solid tumors. The company's therapy specializes in developing virus specific T-cells and CAR T cells for the treatment of lymphoma, enabling healthcare providers to treat cancer patients and improve their lives.
TESSA THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2001-01-01
Address:
Singapore, Central Region, Singapore
Country:
Singapore
Website Url:
http://www.tessacell.com
Total Employee:
101+
Status:
Active
Contact:
(656)384-0755
Total Funding:
256 M USD
Technology used in webpage:
SPF Domain Not Resolving Microsoft Exchange Online Office 365 Mail Person Schema Google Google Cloud Gravatar Profiles Ubuntu Microsoft
Similar Organizations
Amyloid Solution
Amyloid Solution is a developer of therapy intended to overcome Alzheimer by developing modifying treatments.
Atara Biotherapeutics
Atara Biotherapeutics (Nasdaq: ATRA) is an off-the-shelf, allogeneic T-cell immunotherapy company.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Innovative Cellular Therapeutics
Innovative Cellular Therapeutics is a Shanghai-based biotechnology company engaged in research and development of cell therapy.
JW Therapeutics
JW Therapeutics is a developer of cell-based therapy technologies created to revolutionize cancer treatment.
OBiO Technology
OBiO Technology is providing overall solution of viral based gene therapy CRO services, and CDMO/CMO services.
ONK Therapeutics
ONK Therapeutics is an innovative cell therapy organisation.
Pluri
Pluri is at the forefront of a biotech revolution that promotes global well-being and sustainability.
Shanghai Cell Therapy Group
Shanghai Cell Therapy Group is a provider of cellular diagnosis center combining cellular research and treatment services.
Sino Biological
Sino Biological is a specialist provider of protein, antibody and gene products.
Current Advisors List
Board_member
2022-06-09
Board_member
Board_member
2022-06-09
Current Employees Featured
Wilson Cheung Chief Financial Officer @ Tessa Therapeutics
Chief Financial Officer
2022-04-01
Han Chong Toh Chief Medical Officer @ Tessa Therapeutics
Chief Medical Officer
2016-08-01
John Ng Chief Operations Officer & Executive Director @ Tessa Therapeutics
Chief Operations Officer & Executive Director
2016-01-01
Desmond Lim Chief Financial Officer @ Tessa Therapeutics
Chief Financial Officer
2017-12-01
Shian-Jiun Shih Vice President of Product Development @ Tessa Therapeutics
Vice President of Product Development
2016-11-01
Guy Heathers Vice President of Business Development @ Tessa Therapeutics
Vice President of Business Development
2014-09-01
Thomas Willemsen President, Chief Executive Officer, and Board of Directors @ Tessa Therapeutics
President, Chief Executive Officer, and Board of Directors
2022-01-01
John E Connolly Chief Scientific Officer @ Tessa Therapeutics
Chief Scientific Officer
2016-01-01
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2017-03-23 | Euchloe Bio | Euchloe Bio acquired by Tessa Therapeutics | N/A |
Investors List
Heritas Capital
Heritas Capital investment in Series A - Tessa Therapeutics
EDBI
EDBI investment in Series A - Tessa Therapeutics
Temasek Holdings
Temasek Holdings investment in Series A - Tessa Therapeutics
Polaris Partners
Polaris Partners investment in Series A - Tessa Therapeutics
Heliconia Capital Management
Heliconia Capital Management investment in Series A - Tessa Therapeutics
Far East Ventures
Far East Ventures investment in Series E - Tessa Therapeutics
Temasek Holdings
Temasek Holdings investment in Private Equity Round - Tessa Therapeutics
Heliconia Capital Management
Heliconia Capital Management investment in Private Equity Round - Tessa Therapeutics
EDBI
EDBI investment in Private Equity Round - Tessa Therapeutics
Karst Peak Capital
Karst Peak Capital investment in Private Equity Round - Tessa Therapeutics
Newest Events participated
Key Employee Changes
| Date | New article |
|---|---|
| 2022-08-22 | Tessa Therapeutics Appoints Thomas Willemsen as President and CEO |
| 2022-04-04 | Tessa Therapeutics Appoints Wilson W. Cheung as Chief Financial Officer |
Official Site Inspections
http://www.tessacell.com Semrush global rank: 6.03 M Semrush visits lastest month: 1.35 K
- Host name: 104.21.80.1
- IP address: 104.21.80.1
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Tessa Therapeutics"
Tessa Therapeutics - Overview, News & Similar companies
May 11, 2023 A high-level source in Marketing has indicated that the organization is currently sourcing professional services for it delivery & it strategy. See all scoops ... +65 63840755 …See details»
www.tessacell.com
We would like to show you a description here but the site won’t allow us.See details»
Tessa Therapeutics - Crunchbase Company Profile
Tessa Therapeutics is a provider of therapy designed to focus on T cell therapy for solid tumors. The company's therapy specializes in developing virus …See details»
Tessa Therapeutics Company Profile | Management and
Www.tessacell.com Tessa Therapeutics Profile and History Based in Singapore, Tessa Therapeutics is a clinical-stage cell therapy company focused on developing autologous and …See details»
Tessa - Company Profile - Tracxn
Email ID: *****@tessacell.com; Key Metrics. Total Funding. $256M in 3 rounds. Latest Funding Round. Series A, Jun 09, 2022, $126M. Investors. Temasek & 23 more. Ranked. 609 th …See details»
Tessa Therapeutics Ltd - LinkedIn
Tessa Therapeutics Ltd | 21,946 followers on LinkedIn. A clinical-stage biotech company developing autologous and allogeneic cell therapies for the treatment of cancer. | Tessa …See details»
Tessa Therapeutics Saving Lives With a Strong Digital Core
Tessa improved and simplified their global procurement, supply chain, and financial operations throughout the organization. The company benefited from increased visibility of cost allocation, …See details»
Tessa Therapeutics Ltd Overview | SignalHire Company Profile
Tessa Therapeutics Ltd is a private company that has been in the industry for 13 years. The company currently specializes in the Biotechnology, Biotechnology, Pharmaceuticals areas. …See details»
Tessa Therapeutics’ ‘Off-the-Shelf’ CAR-T Therapy Shows …
Jun 16, 2023 Tessa Therapeutics Ltd. 78% Overall Response Rate (14/18 patients), including seven patients exhibiting a complete response to TT11X allogeneic CAR-T therapySee details»
Tessa Therapeutics Appoints Thomas Willemsen as President and …
Seasoned pharmaceutical industry executive to lead Tessa’s corporate and development strategy built around its proprietary autologous and allogeneic CAR-T platforms Appointment follows …See details»
Tessa Therapeutics (Singapore) Funding: $256.1M
Jul 31, 2024 Singapore | Funding: $256.1M Website: https://www.tessacell.com Tessa Therapeutics is a provider of therapy designed to focus on T cell therapy for solid tumors.See details»
Tessa Therapeutics - PitchBook
Tessa Therapeutics General Information Description. Developer of a biotechnology platform designed to focus on developing autologous and allogeneic cell therapies for the treatment of …See details»
Tessa Therapeutics Provides Strategic Outlook and Corporate …
Tessa to prioritize allogeneic CAR-T cell therapy platform following strong safety and efficacy data presented during ASH 2022SINGAPORE, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Tessa …See details»
Tessa Therapeutics Provides Strategic Outlook and Corporate
Jan 3, 2023 For more information on Tessa, visit www.tessacell.com. Cautionary Note on Forward Looking Statements This press release contains forward-looking statements (within …See details»
Tessa Therapeutics Shifts Focus to Allogeneic Therapies
Jan 3, 2023 Tessa Therapeutics will be shifting its focus primarily to allogeneic therapies based on its CD30.CAR-modified Epstein-Barr virus-specific T-cell (EBVST) therapy platform, …See details»
Tessa Therapeutics - Golden
Product candidates in development by Tessa Therapeutics include: Epstein-Barr Virus-Specific T Cells (EBVSTs) for Nasopharyngeal Cancer (NPC), Human Papillomavirus-Specific T Cells …See details»
Tessa Therapeutics Recognized in “Most Promising Off-the-Shelf ...
Sep 14, 2022 Tessa developing allogeneic “off-the-shelf” CD30-CAR EBVST cell therapy – TT11X – targeting relapsed or refractory CD30-positive lymphomasSINGAPORE, Sept. 14, …See details»
Tessa Therapeutics Announces Successful Dosing of First Patient …
Feb 10, 2021 BEDMINSTER, N.J. and SINGAPORE, Feb. 10, 2021 /PRNewswire/ -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation …See details»
Tessa Therapeutics Receives PRIME Designation from European …
Jan 18, 2021 BEDMINSTER, N.J. and SINGAPORE, Jan. 18, 2021 /PRNewswire/ -- Tessa Therapeutics (Tessa), a clinical-stage cell therapy company developing next-generation …See details»
Tessell - The Co-Pilot for your Cloud Databases
Tessell is a database-as-a-service (DBaaS) platform that simplifies the management, security, and scalability of relational databases in the cloud. It supports popular database engines like …See details»